top of page
case studies
case studies
Screening
of novel formulations
/biobetters
There is much research focused on developing new strategies to increase the vitreous residence times of macromolecular drugs to decrease the frequency of intravitreal injections.
The PK-Eye™ is for the evaluation and optimisation of novel ocular formulations and delivery systems for the vitreous. The PK-Eye™ can accelerate the development of longer-lasting therapeutic dosage forms during preclinical development that are needed to treat chronic blinding conditions.
![](https://static.wixstatic.com/media/b7365f_64254fb98977470daead8d92f1412e4c~mv2.png/v1/crop/x_0,y_35,w_1000,h_524/fill/w_525,h_275,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/b7365f_64254fb98977470daead8d92f1412e4c~mv2.png)
Optimisation of a bevacizumab and a protein conjugate (PEG10-Fabrani) hydrogel formulation using the PK-Eye™
Awwad et al, Macromol Biosci. 2018; 18 (2):1700255
bottom of page